# Century Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Century Therapeutics, Inc.).

## Overview

Century Therapeutics, Inc. is a clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer and autoimmune disease. Its platform is designed to create engineered immune cells, including natural killer and T-cell-based product candidates, with the goal of improving consistency, scalability, and manufacturing control versus donor-derived approaches. The company is still in the development phase and has not generated product sales; its historical revenue has come from collaboration arrangements. Century Therapeutics is building both its pipeline and its own manufacturing capabilities, including a flexible cell therapy facility in Branchburg, New Jersey. The business is highly dependent on advancing a small number of early-stage programs and securing future collaboration or financing support.

## Products & services

• iPSC-derived cell therapy platform
• CNTY-101 clinical program
• CNTY-813 product candidate
• CNTY-308 product candidate
• Cell therapy manufacturing and process development
• Collaboration, option and license agreements

- **Cell therapy product candidates** (0%) — Engineered iPSC-derived immune cell therapies in clinical and preclinical development for oncology and autoimmune indications.
- **Platform technology and R&D services** (0%) — Discovery, process development, product characterization, and analytical work supporting the cell therapy pipeline.
- **Collaboration and license revenue** (100%) — Revenue recognized from partner agreements, including option, license, and collaboration arrangements.

- iPSC-derived cell therapy platform
- CNTY-101 clinical program
- CNTY-813 product candidate
- CNTY-308 product candidate
- Cell therapy manufacturing and process development
- Collaboration, option and license agreements

## Customers

Century Therapeutics does not currently sell commercial products to end patients or healthcare providers. Its direct counterparties are pharmaceutical and biotechnology partners that enter into collaboration, option, and license agreements to access its iPSC cell therapy platform and pipeline assets. The company also works with contract and manufacturing partners, such as FUJIFILM Cellular Dynamics, for clinical supply in certain programs. In the future, if product candidates are approved, the ultimate customers would be hospitals, physicians, and payors, but that remains a downstream opportunity rather than a current revenue source. Today, the business model is primarily partner-funded research and development rather than product commercialization.

- **Strategic pharmaceutical partners** (primary) — Companies that enter collaboration, option, or license agreements to fund development and gain access to Century's cell therapy programs.
- **Biotechnology collaboration partners** (primary) — Smaller biopharma companies that may co-develop or in-license platform assets to accelerate research and clinical development.
- **Manufacturing and supply partners** (secondary) — Third-party manufacturers and service providers that produce clinical material or support process development for trials.
- **Clinical research ecosystem** (secondary) — Investigators, trial sites, and patient recruitment networks that enable execution of early clinical studies.

- Pharmaceutical partners that license or collaborate on pipeline assets
- Biotechnology partners seeking access to iPSC cell therapy technology
- Manufacturing collaborators and CDMO-type suppliers for clinical supply
- Clinical investigators and trial sites supporting patient enrollment
- Future healthcare providers and payors, if products are approved

## Geography

Century Therapeutics is headquartered in the United States and conducts most of its research, development, and manufacturing activities there. Its in-house cell therapy manufacturing facility is located in Branchburg, New Jersey, and the company also uses FUJIFILM Cellular Dynamics' cGMP facility in Madison, Wisconsin for certain clinical supply. The company received a QP declaration in February 2025 to support clinical supply from its own facility for EU studies, indicating an ability to serve both U.S. and European clinical programs. Geography matters mainly because manufacturing location, regulatory compliance, and clinical trial supply logistics directly affect development timelines and cost. The company does not disclose country-level revenue concentration in the provided excerpts, and its revenue is currently driven by collaboration arrangements rather than geographic end-market sales.

- United States is the core operating base for R&D and manufacturing
- Branchburg, New Jersey facility is the main in-house cell therapy site
- Madison, Wisconsin facility is used for clinical supply via FCDI
- EU clinical supply capability expanded after QP declaration in 2025
- No country-level revenue mix was disclosed in the provided excerpts

## Strategy

Century Therapeutics is focused on advancing a concentrated pipeline of iPSC-derived cell therapies, with CNTY-101 highlighted as a key clinical program and CNTY-813 and CNTY-308 as important follow-on candidates. A central strategic priority is to build internal manufacturing, process analytics, and product characterization capabilities so the company can better control development timelines and improve scalability. The company is also investing in a flexible multi-product facility to support multiple cell types and reduce dependence on external supply for future programs. Because it has no product revenue, Century expects to fund operations through existing cash, future equity or debt financing, and any future collaboration, milestone, or royalty payments. In practical terms, the strategy is about extending runway, reducing manufacturing bottlenecks, and creating enough clinical and platform value to attract partners or eventual commercialization opportunities.

- **Advance lead clinical and preclinical programs** (short-term) — The company is highly dependent on a small number of programs, so clinical progress is essential to create value and attract partners.
- **Build internal manufacturing capabilities** (medium-term) — Owning more of the manufacturing process should improve control over timelines, quality, and scalability while reducing reliance on third parties.
- **Secure external funding and collaborations** (short-term) — The company expects to need additional financing and future collaboration revenue to support ongoing R&D and clinical work.

- Advance CNTY-101 and other early pipeline assets through clinical development
- Expand in-house manufacturing control to reduce timeline and supply risk
- Invest in process analytics and product characterization for better quality control
- Use a flexible multi-product facility to support multiple cell types
- Seek future collaborations to fund R&D and validate the platform
- Raise additional capital to finance preclinical, clinical, and commercialization work

## Risks

Century Therapeutics faces the classic risks of a clinical-stage biotech company: its pipeline is concentrated in a limited number of early-stage programs, and failure to advance them would materially harm the business. The company also depends on future financing and collaboration revenue, so any inability to raise capital or replace the terminated Bristol-Myers Squibb agreement would pressure operations and runway. Manufacturing execution is another key risk because cell therapy products are complex, sensitive to supply-chain handling, and dependent on cGMP compliance and process consistency. Competitive risk is high, as larger pharmaceutical companies and better-funded biotech peers may develop safer, more effective, or faster-to-market therapies, including non-cell therapy alternatives such as bispecific antibodies and T-cell engagers. Regulatory, clinical trial, and healthcare-law compliance risks are also material because approval timelines, patient enrollment, and fraud-and-abuse rules can affect both development and eventual commercialization.

- **Pipeline concentration in a small number of early-stage programs** [high] — The company states that failure to advance its limited preclinical and clinical programs would materially harm the business.
- **Need for additional financing** [high] — Century expects to raise more capital to fund preclinical studies, clinical trials, and commercialization activities.
- **Loss of collaboration revenue** [high] — Historical revenue came from the Bristol-Myers Squibb collaboration, which was terminated effective March 12, 2025.
- **Manufacturing and supply-chain complexity** [medium] — Cell therapy production requires cGMP compliance, cryopreservation control, and reliable clinical supply across sites.
- **Competitive pressure from larger and better-funded peers** [medium] — Competitors may reach regulatory approval faster or develop more effective therapies, reducing Century's commercial opportunity.

- Pipeline concentration risk if CNTY-101 and other programs fail
- Financing risk because the company expects to need additional capital
- Collaboration revenue risk after termination of the Bristol-Myers Squibb agreement
- Manufacturing and supply-chain risk for complex cell therapy products
- Clinical trial execution risk, including enrollment and site availability
- Competitive risk from larger biopharma and alternative modalities
- Regulatory and healthcare-law compliance risk across development and promotion

## Accounting

Century Therapeutics' most important accounting issue is collaboration revenue recognition, because the company has not generated product sales and has historically recognized revenue over the expected performance period of partner agreements. The termination of the Bristol-Myers Squibb collaboration makes revenue timing and the absence of replacement agreements especially important for quarter-to-quarter comparability. Research and development costs are expensed as incurred, so clinical and manufacturing ramp-up flows directly through the income statement rather than being capitalized. The company also relies on estimates for prepaid R&D, acquired in-process R&D, and other judgmental items tied to early-stage development activities. As a smaller reporting company and clinical-stage biotech, it may also face significant volatility in reported results because small changes in collaboration milestones, trial timing, or manufacturing spend can materially affect quarterly losses.

- **Collaboration revenue recognition** — Quarterly revenue volatility and timing differences
- **Research and development expense recognition** — High operating loss volatility
- **Prepaid expenses and accrued R&D** — Period-to-period comparability
- **Estimates for early-stage development costs** — Judgment-sensitive expense recognition

- Collaboration revenue is recognized over the expected performance period
- No product sales means reported revenue depends on partner agreements
- R&D is expensed as incurred, increasing volatility as programs advance
- Prepaid R&D and third-party service timing affect quarterly expense recognition
- Clinical-stage estimates can change with trial timing and development scope
- Future milestone or royalty accounting could create uneven revenue periods

---

*Last updated: 2026-04-28T14:26:22.228478+00:00*